AXNX:NSD-Axonics Modulation Technologies Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 67.45

Change

+0.12 (+0.18)%

Market Cap

USD 3.44B

Volume

0.40M

Analyst Target

USD 52.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-14 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 50.65B
ALGN Align Technology Inc

N/A

USD 19.24B
PODD Insulet Corporation

N/A

USD 12.61B
SWAV Shockwave Medical Inc

N/A

USD 12.57B
BRKR Bruker Corporation

N/A

USD 11.23B
MASI Masimo Corporation

N/A

USD 6.74B
TMDX TransMedics Group Inc

N/A

USD 4.62B
PRCT Procept Biorobotics Corp

N/A

USD 3.54B
TNDM Tandem Diabetes Care Inc

N/A

USD 3.20B
IRTC iRhythm Technologies Inc

N/A

USD 3.02B

ETFs Containing AXNX

IBRN iShares Trust - iShares N.. 4.64 % 0.00 %

N/A

USD 3.84M
MARB First Trust Vivaldi Merge.. 4.00 % 0.00 %

N/A

USD 0.04B
ARB AltShares Trust - AltShar.. 2.74 % 0.00 %

N/A

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.39% 72% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.39% 72% C 71% C-
Trailing 12 Months  
Capital Gain 27.26% 81% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.26% 81% B- 75% C
Trailing 5 Years  
Capital Gain 123.71% 91% A- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 123.71% 91% A- 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 24.14% 72% C 82% B
Dividend Return 24.14% 71% C- 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.58% 73% C 44% F
Risk Adjusted Return 59.50% 95% A 86% B+
Market Capitalization 3.44B 94% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.